Cargando…

Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry

PURPOSE: Pancreatic cancer is one of the most malignant cancers with poor survival. The latest edition of the American Joint Committee on Cancer (AJCC) staging system classifies the majority of operable pancreatic cancer patients as stage-III, while dramatic heterogeneity is observed among these pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Tzu-Pin, Wu, Chien-Hui, Chang, Chia-Chen, Chan, Han-Ching, Chattopadhyay, Amrita, Lee, Wen-Chung, Chiang, Chun-Ju, Lee, Hsin-Ying, Tien, Yu-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810458/
https://www.ncbi.nlm.nih.gov/pubmed/34775547
http://dx.doi.org/10.1245/s10434-021-11030-w
_version_ 1784644257484636160
author Lu, Tzu-Pin
Wu, Chien-Hui
Chang, Chia-Chen
Chan, Han-Ching
Chattopadhyay, Amrita
Lee, Wen-Chung
Chiang, Chun-Ju
Lee, Hsin-Ying
Tien, Yu-Wen
author_facet Lu, Tzu-Pin
Wu, Chien-Hui
Chang, Chia-Chen
Chan, Han-Ching
Chattopadhyay, Amrita
Lee, Wen-Chung
Chiang, Chun-Ju
Lee, Hsin-Ying
Tien, Yu-Wen
author_sort Lu, Tzu-Pin
collection PubMed
description PURPOSE: Pancreatic cancer is one of the most malignant cancers with poor survival. The latest edition of the American Joint Committee on Cancer (AJCC) staging system classifies the majority of operable pancreatic cancer patients as stage-III, while dramatic heterogeneity is observed among these patients. Therefore, subgrouping is required to accurately predict their prognosis and define a treatment plan. This study conducts a cohort study to provide a more precise classification system for stage-III pancreatic cancer patients by utilizing clinical variables. METHODS: We analyzed survival using log-rank tests, univariate Cox-regression models, and Kaplan-Meier survival curves for stage-III pancreatic ductal adenocarcinoma (PDAC) patients from the Taiwan Cancer Registry (TCR). Patients were further divided into subgroups using classification and regression tree (CART) algorithm. All results were validated using the SEER database. RESULTS: Among stage-III PDAC patients, lymph node and tumor grade showed significant association with survival. Patients with N2 stage had higher mortality risks (hazard ratio [HR] = 2.30, 95% confidence interval [CI] 1.71–3.08, p < 0.0001) than N0 patients. Patients with grade 3 also had higher risk of mortality (HR = 3.80, 95% CI 2.25–6.39, p < 0.0001) than grade 1 patients. The CART algorithm stratified stage-III patients into four subgroups with significantly different survival rates. The median survival of the four subgroups was 23.5, 18.4, 14.5, and 9.0 months, respectively (p < 0.0001). Similar results were observed with SEER data. CONCLUSIONS: Lymph node involvement and tumor grade are predictive factors for survival in stage-III PDAC patients. This new precise classification system can be used to guide treatment planning in advanced-stage pancreatic cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-021-11030-w.
format Online
Article
Text
id pubmed-8810458
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88104582022-02-17 Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry Lu, Tzu-Pin Wu, Chien-Hui Chang, Chia-Chen Chan, Han-Ching Chattopadhyay, Amrita Lee, Wen-Chung Chiang, Chun-Ju Lee, Hsin-Ying Tien, Yu-Wen Ann Surg Oncol Pancreatic Tumors PURPOSE: Pancreatic cancer is one of the most malignant cancers with poor survival. The latest edition of the American Joint Committee on Cancer (AJCC) staging system classifies the majority of operable pancreatic cancer patients as stage-III, while dramatic heterogeneity is observed among these patients. Therefore, subgrouping is required to accurately predict their prognosis and define a treatment plan. This study conducts a cohort study to provide a more precise classification system for stage-III pancreatic cancer patients by utilizing clinical variables. METHODS: We analyzed survival using log-rank tests, univariate Cox-regression models, and Kaplan-Meier survival curves for stage-III pancreatic ductal adenocarcinoma (PDAC) patients from the Taiwan Cancer Registry (TCR). Patients were further divided into subgroups using classification and regression tree (CART) algorithm. All results were validated using the SEER database. RESULTS: Among stage-III PDAC patients, lymph node and tumor grade showed significant association with survival. Patients with N2 stage had higher mortality risks (hazard ratio [HR] = 2.30, 95% confidence interval [CI] 1.71–3.08, p < 0.0001) than N0 patients. Patients with grade 3 also had higher risk of mortality (HR = 3.80, 95% CI 2.25–6.39, p < 0.0001) than grade 1 patients. The CART algorithm stratified stage-III patients into four subgroups with significantly different survival rates. The median survival of the four subgroups was 23.5, 18.4, 14.5, and 9.0 months, respectively (p < 0.0001). Similar results were observed with SEER data. CONCLUSIONS: Lymph node involvement and tumor grade are predictive factors for survival in stage-III PDAC patients. This new precise classification system can be used to guide treatment planning in advanced-stage pancreatic cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-021-11030-w. Springer International Publishing 2021-11-13 2022 /pmc/articles/PMC8810458/ /pubmed/34775547 http://dx.doi.org/10.1245/s10434-021-11030-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Pancreatic Tumors
Lu, Tzu-Pin
Wu, Chien-Hui
Chang, Chia-Chen
Chan, Han-Ching
Chattopadhyay, Amrita
Lee, Wen-Chung
Chiang, Chun-Ju
Lee, Hsin-Ying
Tien, Yu-Wen
Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry
title Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry
title_full Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry
title_fullStr Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry
title_full_unstemmed Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry
title_short Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry
title_sort distinct survival outcomes in subgroups of stage iii pancreatic cancer patients: taiwan cancer registry and surveillance, epidemiology and end results registry
topic Pancreatic Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810458/
https://www.ncbi.nlm.nih.gov/pubmed/34775547
http://dx.doi.org/10.1245/s10434-021-11030-w
work_keys_str_mv AT lutzupin distinctsurvivaloutcomesinsubgroupsofstageiiipancreaticcancerpatientstaiwancancerregistryandsurveillanceepidemiologyandendresultsregistry
AT wuchienhui distinctsurvivaloutcomesinsubgroupsofstageiiipancreaticcancerpatientstaiwancancerregistryandsurveillanceepidemiologyandendresultsregistry
AT changchiachen distinctsurvivaloutcomesinsubgroupsofstageiiipancreaticcancerpatientstaiwancancerregistryandsurveillanceepidemiologyandendresultsregistry
AT chanhanching distinctsurvivaloutcomesinsubgroupsofstageiiipancreaticcancerpatientstaiwancancerregistryandsurveillanceepidemiologyandendresultsregistry
AT chattopadhyayamrita distinctsurvivaloutcomesinsubgroupsofstageiiipancreaticcancerpatientstaiwancancerregistryandsurveillanceepidemiologyandendresultsregistry
AT leewenchung distinctsurvivaloutcomesinsubgroupsofstageiiipancreaticcancerpatientstaiwancancerregistryandsurveillanceepidemiologyandendresultsregistry
AT chiangchunju distinctsurvivaloutcomesinsubgroupsofstageiiipancreaticcancerpatientstaiwancancerregistryandsurveillanceepidemiologyandendresultsregistry
AT leehsinying distinctsurvivaloutcomesinsubgroupsofstageiiipancreaticcancerpatientstaiwancancerregistryandsurveillanceepidemiologyandendresultsregistry
AT tienyuwen distinctsurvivaloutcomesinsubgroupsofstageiiipancreaticcancerpatientstaiwancancerregistryandsurveillanceepidemiologyandendresultsregistry